The Biostatistics, Analytical Support &Evaluation Shared Resource (BASE SR) provides comprehensive biostatistics and bioinformatics support to cancer-related research at UCLA. The BASE SR was established in 1994 and has been directed by Dr. Gang Li (CMI) since 2007. In addition to Li, the BASE SR also includes seven faculty members from the UCLA Departments of Biostatistics, Biomathematics, Human Genetics and Medicine, two staff biostatisticians and a program coordinator. All of these individuals have expertise in general biostatistics, the design and analysis of clinical trials and analysis of tissue arrays and next generation sequencing data. The BASE SR provides services for JCCC members who conduct both basic and clinical research. This includes critical support for the design of studies prior to grant submission, with statisticians supported as co-investigators if funding is obtained. In addition, the BASE SR provides support for JCCC protocol review, approval functions of the Internal Scientific Peer Review Committee (JCCC's PRMC), Data Safety and Monitoring Board and the Internal Quality Assurance Committee. The BASE SR also reviews clinical trials funded by pharmaceutical companies that are conducted in our clinical trials network, TRIO (Translational Research in Oncology). When needed, novel statistical methodology will be developed to facilitate studies. Peer-reviewed, funded research projects of JCCC investigators represent the highest priority. From 07/01/2011-06/30/2012, the BASE Shared Resource had 89 users, 66 of whom were JCCC members, representing seven Cancer Center Program Areas. Of the 89 member users, 49 had peer-reviewed funding and 17 did not have peer-reviewed funding. The role of the BASE SR in the facilitation of study design, data analysis, grant applications, protocol review, design and implementation of clinical trials and data management is central to the mission of JCCC.
Statistical analysis is essential in order to interpret basic research results, such as complex data sets obtained from next generation sequencing, as well as to evaluate the outcome of clinical trials. The BASE SR provides such state-of-the-art services to support JCCC researchers in their quest to unravel the causes of cancer and to develop the most efficacious ways to treat it.
|Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84|
|Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37|
|Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40|
|Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14|
|Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17|
|Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7|
|Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15|
|Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27|
|Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206|
|De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7|
Showing the most recent 10 out of 192 publications